MANA-677679 is under clinical development by Mana Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MANA-677679’s likelihood of approval (LoA) and phase transition for Ependymoma took place on 20 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 20 Jul 2022 increased MANA-677679’s Phase Transition Success Rate (PTSR) for High-Grade Glioma, increased PTSR for Medulloblastoma, and increased PTSR for Pediatric Diffuse Intrinsic Pontine Glioma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MANA-677679 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MANA-677679 overview

MANA-677679 (TAA-T) is under investigation for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), ambiguous lineage leukemia or lymphoma, chronic myelogenous leukemia (CML), myelodysplastic syndrome, diffuse intrinsic pontine glioma, medulloblastoma, ependymoma, embryonal tumors, choroid plexus carcinoma, other aggressive CNS malignancies, Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcomas, osteosarcoma, and adenocarcinoma. The therapy is administered parenterally. It constitutes a tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes which act by targeting cancer cells which express WT1, prame, survivin, and mage-A3 tumor-associated antigens.

Mana Therapeutics overview

Mana Therapeutics, is a clinical stage biopharmaceutical company that developing next-generation, off-the-shelf, allogeneic T-cell therapies with its multi-tumor associated antigen T-cell (MTAA-T cells) for cancer indications. The company is headquart

Quick View MANA-677679 LOA Data

Report Segments
  • Innovator
Drug Name
  • MANA-677679
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.